Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03331835
Recruitment Status : Completed
First Posted : November 6, 2017
Results First Posted : February 10, 2020
Last Update Posted : February 19, 2020
Sponsor:
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
The primary objective is to demonstrate added benefit of brodalumab versus a selected systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in subjects who have not previously received systemic treatment for psoriasis. > Fumaric acid esters have been selected as the comparator because it is an established systemic treatment of psoriasis in Germany.>

Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Biological: Brodalumab Drug: Fumaric acid esters Phase 4

Detailed Description:
A 24-week, randomised, open-label, active-controlled, parallel group, multi-centre trial with investigator-blinded efficacy assessments

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 210 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
Actual Study Start Date : November 3, 2017
Actual Primary Completion Date : January 24, 2019
Actual Study Completion Date : March 21, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Brodalumab
Kyntheum® (brodalumab)> pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.> First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
Biological: Brodalumab
Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).> Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis.
Other Name: Kyntheum®

Active Comparator: Fumaric acid esters

Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)> Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)>

> Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label.

Drug: Fumaric acid esters
Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
Other Name: Fumaderm®




Primary Outcome Measures :
  1. Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24 [ Time Frame: Baseline to Week 24 ]

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region.

    Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).


  2. Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24 [ Time Frame: Baseline to Week 24 ]

    sPGA is a 6-point scale that represents the average lesion severity on the trunk and limbs. The assessment is based on the condition of the disease at the time of evaluation.

    Static Physician's Global Assessment is a scale ranging rom 0 (clear skin) to 5 (severe disease).



Secondary Outcome Measures :
  1. Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24 [ Time Frame: Baseline to Week 24 ]

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region.

    Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).


  2. Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24 [ Time Frame: Baseline to Week 24 ]

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region.

    Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).


  3. Change From Baseline at Week 24 in PASI Score [ Time Frame: Baseline to Week 24 ]

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).

    A negative change in PASI score means that the PASI score was lower at the time of data collection.


  4. Percent Change From Baseline in PASI Score at Week 24 [ Time Frame: Baseline to Week 24 ]

    The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region. Psoriasis Area and Severity Index is a scale ranging from 0 (no disease) to 72 (maximal disease).

    A negative value in the percent change from baseline that the PASI score was lower at the time of data collection.


  5. Change From Baseline at Week 24 in Affected Body Surface Area (BSA) [ Time Frame: Baseline to Week 24 ]

    The surface area of the participant's hand (palm and fingers) is used as a reference measurement to calculate the percentage of each body region that is affected by psoriasis. One hand is approximately equal to 1% total BSA.

    Furthermore, the complete body surface area (BSA=100%) can be divided into regions that approximates percentages of BSA as follows: head and neck (10%), upper extremities (20%), the trunk including the axillae and groin (30%), and finally the lower extremities, including the buttocks (40%).

    A negative value in the percent change from baseline that the affected BSA was lower at the time of data collection.


  6. Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1) [ Time Frame: Week 24 ]
    The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score >1. Symptom-free day is defined as having daily total PSI of 0 on that day.

  7. PSI Total Score of 0 at Week 24 [ Time Frame: Week 24 ]
    The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score >1. Symptom-free day is defined as having daily total PSI of 0 on that day.

  8. Number of Symptom-free Days From Randomisation to Week 24 [ Time Frame: Baseline to Week 24 ]
    The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms. PSI response is defined as total score ≤8 and no item score >1. Symptom-free day is defined as having daily total PSI of 0 on that day.

  9. Burden of Symptoms [ Time Frame: Baseline to Week 24 ]

    Burden of symptoms was assessed as the normalised area under the curve (AUC) of PSI from baseline to the last available assessment. The AUC for the PSI total score was calculated for each participant using the standard trapezoidal rule. The AUC was normalised by dividing it with the time from baseline to the last available assessment of the PSI total score.

    The PSI consists of eight psoriasis-specific questions. Trial participants rated the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms.


  10. Change From Baseline at Week 24 in Dermatology Life Quality Index (DLQI) Total Score [ Time Frame: Baseline to Week 24 ]
    DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.

  11. DLQI Total Score of 0 or 1 at Week 24 [ Time Frame: Week 24 ]
    DLQI consists of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.


Other Outcome Measures:
  1. Change From Baseline at Week 24 in NAPSI Total Score [ Time Frame: Baseline to Week 24 ]

    The Nail Psoriasis Severity Index (NAPSI) grades nails by first dividing the nail area with imaginary horizontal and vertical lines into 4 quarters. The following 8 clinical features of nail psoriasis are then scored based on the number of quarters in which the feature is present (0 to 4) to arrive at a NAPSI score of 0 to 32 for each nail:

    • Pitting.
    • Leukonychia.
    • Red spots in lunula.
    • Nail plate crumbling.
    • Oil drop (salmon patch) discoloration.
    • Onycholysis.
    • Nail bed hyperkeratosis.
    • Splinter haemorrhages.

    A negative change in NAPSI score means that the NAPSI score was lower at the time of data collection.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Criteria for Inclusion:>

  • Men or women ≥18 years of age at the time of screening.>
  • Subjects with chronic plaque type psoriasis diagnosed at least 6 months before randomisation.>
  • Subjects with moderate to severe plaque psoriasis in whom topical therapy is not adequate and who are candidates for systemic therapy, defined at randomisation by PASI >10, affected BSA >10%, and DLQI >10.>
  • Subject has no known history of active tuberculosis.>
  • Subject has a negative test for tuberculosis taken at screening (negative Quantiferon test).>
  • Subject and/or subject's designee is/are capable of administering subcutaneous injections.>

Main Criteria for Exclusion:>

  • Previous or current systemic treatment of plaque psoriasis or known contraindication for systemic therapy.>
  • Previous or current PUVA (psoralens and ultraviolet A) therapy.>
  • Washouts and non-permitted drugs:>

    1. Have received phototherapy (UVA light therapy without psoralens, UVB light therapy, excimer laser, tanning beds etc. within 4 weeks of baseline, or>
    2. Have had topical psoriasis treatment within 2 weeks of baseline (exceptions: bland emollients without urea or beta or alpha hydroxy acids)>
    3. Have received any biologic immune modulating treatments used for indication other than psoriasis within 4 weeks of baseline or within a period of 5 half-lives of the IMP, whichever is longer>
    4. Have received any other systemic immune modulating treatment (including but not limited to oral retinoids, methotrexate, calcineurin inhibitors, oral or parenteral corticosteroids etc. used for indications other than psoriasis) within 4 weeks of baseline or within a period of 5 half-lives of the IMP, whichever is longer.>
  • Subjects with any of the following laboratory abnormalities at screening:>

    1. Leukocyte cell count below 3×10^9/L or lymphocyte count below 0.7×10^9/L>
    2. Aspartate aminotransferase (AST) or alanine transferase (ALT) > 2× ULN (upper level of normal limit)>
    3. Absolute neutrophil count < 2×10^9/L>
    4. Serum creatinine > ULN.>
  • History of depressive disorder within the last 2 years including current antidepressive treatment.>
  • Subjects with a history of suicidal behaviour (suicide attempt). >
  • Any suicidal ideation of severity 4 or 5 based on the eC-SSRS questionnaire at screening.>
  • A PHQ-8 score of ≥10 corresponding to moderate to severe depression at screening.>

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03331835


Locations
Show Show 30 study locations
Sponsors and Collaborators
LEO Pharma
Investigators
Layout table for investigator information
Study Director: Study Director LEO Pharma
  Study Documents (Full-Text)

Documents provided by LEO Pharma:
Layout table for additonal information
Responsible Party: LEO Pharma
ClinicalTrials.gov Identifier: NCT03331835    
Other Study ID Numbers: LP0160-1327
2016-003867-21 ( EudraCT Number )
First Posted: November 6, 2017    Key Record Dates
Results First Posted: February 10, 2020
Last Update Posted: February 19, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Brodalumab
Dermatologic Agents